Aaron Katz, Md, To Lead Study And Contribute To Developing Cryo-On-Line Database (Cold Registry), Outcomes Data Related To Prostate Cryosurgery

November 5, 2004

IRVINE, CA (November 2, 2004) . . . Endocare, Inc. (ENDO.PK) an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation along with vacuum technologies for erectile dysfunction, today announced that it has entered a research agreement with Columbia University Medical Center and Aaron Katz, M.D. to assess, broaden, and report significant findings related to the company’s Cryo-On-Line Database (COLD Registry), a worldwide repository for outcomes data related to prostate cryosurgery.

Under the terms of the agreement, Dr. Katz and his staff will utilize the COLD Registry for patient records from NewYork-Presbyterian Hospital/Columbia University Medical Center and other centers across the county and submit the findings in the form of clinical research papers for publication in national medical journals and other publications.

Dr. Katz, Associate Professor of Clinical Urology at the College of Physicians and Surgeons at Columbia University Medical Center in New York, and a pioneer in the clinical use of cryotherapy, said that his lengthy and positive experience with the Cryocare™ technology has led him to take on this research project.

“We are pleased that our work with Endocare will enable the creation of a substantial clinical outcomes database for the treatment of prostate cancer with cryosurgery,” said Dr. Katz. “As the COLD Registry will pool data from doctors around the country, the database should speed our understanding of the clinical benefits of this treatment and the role it should continue to play in prostate cancer treatment.”

Chairman and CEO of Endocare, Craig T. Davenport, stated, “Dr. Katz is certainly one of the pioneers in the treatment of cancer with freezing technologies and has, along with other thought leaders, been using the Cryocare system for many years. We welcome his continued involvement with our company and our research efforts and look forward to the further development of the COLD Registry and to the resulting analysis and reporting of that data. We believe that the COLD Registry can become a leading resource for physicians and patients to gain the information needed to make a wise decision about how to tackle this disease.”

Dr. Katz has spoken at numerous meetings, conferences and symposia in the U.S. and abroad and is widely published, in the Journal of Urology, Contemporary Urology, Molecular Urology, British Journal of Urology, Cancer, and Cancer Research. Dr. Katz is a member of the American Urological Association, the Society of Urologic Cryosurgeons, the Society of University Urologists and the Southwest Oncology Group. Over the course of his career, Dr. Katz has won numerous awards and grants, including one from the NIH to study the molecular staging of prostate cancer, as well as one from CaPCure for the investigation of an antibody to prevent the recurrence of prostate cancer.

Endocare, Inc.—www.endocare.com— is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing devices for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung, liver and bone.

Columbia University Medical Center provides international leadership in basic and clinical research, medical education, and health care. The medical center includes the dedicated work of many physicians, scientists, and other health professionals at the College of Physicians & Surgeons, the School of Dental & Oral Surgery, the School of Nursing, the Mailman School of Public Health, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. The pioneering achievements of Columbia University health scientists, who contributed some of the 20th century's most significant medical breakthroughs, continues today.

Statements contained in this release that are not historical facts are forward-looking statements that involve risks and uncertainties. Among the important factors which could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, those discussed in “Risk Factors” in the Company’s Forms 10-K, Forms 10-Q, and other filings with the Securities and Exchange Commission. Such risk factors include, but are not limited to: negative results in pending litigation; uncertainty relating to ongoing investigations by governmental agencies; changes in and/or attrition to the Company’s senior management; limited operating history of the Company with a history of losses; uncertainty regarding market acceptance of the Company’s products; uncertainty of product development and the associated risks related to clinical trials; the Company’s ability to integrate acquisitions; uncertainty relating to third party reimbursement; ability to convince health care professionals and third party payers of the medical and economic benefits of the Company’s products; difficulty in managing growth; the Company’s limited sales, marketing and manufacturing experience; ability to attract and retain key personnel; ability to secure and protect intellectual property rights relating to the Company’s technology; the rapid pace of technological change in the Company’s industry; fluctuations in the Company’s order levels; uncertainty regarding the timing of filing of the Company’s periodic reports; and the Company’s successful relisting on NASDAQ. The actual results that the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. We undertake no obligation to revise, or update publicly, any forward-looking statements for any reason.




Associate Professor, Cancer Research, NASDAQ, PK